Investor Newsletter

Issue 08 2023

MicroPort®

MicroPort® Participates in SRS 2023

Between July 24-26, the Annual Meeting of the Society for Robotic Surgery 2023 (SRS 2023) was successfully held in Melbourne, Australia. Three products from Shanghai MicroPort MedBot (Group) Co., Ltd. (MicroPort® MedBot™), namely the Toumai® Four-arm Laparoscopic Surgical Robot (Toumai®), the SkyWalker™ Orthopedic Surgical Robot (SkyWalker™), and the Evolution® Medial-Pivot Knee System (Evolution®) from MicroPort® Orthopedics Inc. (MicroPort® Orthopedics) were showcased at this academic event. They demonstrated the innovative advantages and technical strengths of China's surgical robots to over 1,400 experts and scholars from around the world. These products attracted many domestic and foreign attendees who wished to experience and test-drive them, with their operational performance receiving wide recognition.

Jake Adams emphasized that the combination of SkyWalker™ and MicroPort® Orthopedics' Evolution® Medial-Pivot Knee System can integrate the kinematics of the medial pivot knee, real-time gap balance, and intraoperative data to optimize SkyWalker™'s operation further, providing patients with accurate knee replacement surgery solutions and improving patients' postoperative quality of life – which could be described as a 'Power of Three'.

Finally, Jake Adams also demonstrated a knee replacement surgery performed by Professor Hao Zhong from the First People's Hospital of Huizhou City, Guangdong Province, for a 70-year-old female patient. By reviewing the preoperative and intraoperative steps of SkyWalker™, the attending experts directly saw how SkyWalker™ assisted doctors in standardizing and precisely completing surgery, promoting quicker patient recovery with less trauma, which earned widespread recognition from the attending experts.

MicroPort

MicroPort® Coronary's Firefighter™ NC Pro Balloon Dilation Catheter Receives Approval in the USA

Recently, Shanghai MicroPort Medical (Group) Co., Ltd. (MicroPort® Coronary) announced that its Firefighter™ NC Pro PTCA Balloon Catheter (Firefighter™ NC Pro) had obtained market authorization from the US Food and Drug Administration (FDA).

As a new generation of high-pressure balloon catheters launched by MicroPort® Coronary, the Firefighter™ NC Pro aims to enhance myocardial perfusion and is designed for balloon dilation of narrowed sections of coronary arteries or coronary artery bypass grafts. It is also applicable to post-dilation after stent implants. The Firefighter™ NC Pro adopts a three-layer composite material design for the balloon, with a maximum rated burst pressure of up to 22 atmospheres. This ensures effective dilation by effectively suppressing highly-resistant lesions like calcifications. Due to its design, it has an ultra-low compliance feature that significantly decreases the 'dog bone' phenomenon, whereby a patient intermittently experiences pain in a specific area after initial relief, reminiscent of a dog obsessing over a bone. This helps achieve precise dilation while minimizing surgical trauma and reducing balloon slippage during operations.

With its approval for sale in the United States, Firefighter™ NC Pro further expands MicroPort® Coronary's balloon product line in the overseas market, providing more choices for doctors and patients. In the future, MicroPort® Coronary will continue to adhere to quality leadership and innovation-driven principles, always holding true to the initial intention of wholeheartedly safeguarding every patient with coronary heart disease to provide more high-quality, affordable, integrated solutions for patients and doctors worldwide.

MicroPort

Jin et al. BMC Surgery (2023) 23:164
https://doi.org/10.1186/s12893-023-02049-9

BMC Surgery

RESEARCH Open Access

Randomized, prospective, multicenter trial assessing the numen coil embolization system in the endovascular treatment of small intracranial aneurysms: outcomes from the CATCH Trial

Yazhou Jin[1], Xinbin Guo[1], Tao Quan[1], Rui Zhao[2], Tianxiao Li[3], Zhenwei Zhao[4], Hua Yang[5], Xingen Zhu[6], Guobiao Liang[7], Bing Leng[8], Xin Wu[9], Yang Wang[10] and Sheng Guan[1*]



MicroPort® NeuroTech™ NUMEN®'s Research Results are Published in BMC Surgery

The research results of the NUMEN™ Coil Embolization System (NUMEN™) developed by MicroPort NeuroTech (Shanghai) Co., Ltd. (MicroPort® NeuroTech™), applied to small intracranial aneurysms, have been officially published in the Journal, BMC Surgery.

The CATCH clinical trial was a prospective, multicenter, randomized controlled clinical study conducted in China to investigate the efficacy and safety of coil embolism treatment for intracranial aneurysms. The trial adhered to international standards and was led by Professor Jianmin Liu from the Cerebrovascular Disease Center of Shanghai Changhai Hospital in collaboration with nine renowned neuro-interventional centers across the country.

According to Professor Sheng Guan, "Not only should domestic neuro-interventional devices be on par with international standards in terms of design, technology, and actual results, but all aspects, including preclinical and clinical research phases, should also be summarized scientifically and strive for SCI publication to fully align with global neuro-interventional standards. It's gratifying to observe the efforts of the relevant R&D and application personnel of the NUMEN™ project and their outstanding achievements. I hope more domestic enterprises and products will reach the international stage."

MicroPort



MicroPort® MedBot™'s SkyWalker™ is approved for sale by TGA of Australia

Recently, the SkyWalker™ Orthopedic Surgical Robot, developed by Suzhou MicroPort NaviBot (Suzhou) Co., Ltd., a subsidiary of Shanghai MicroPort MedBot (Group) Co., Ltd. (MicroPort® MedBot™) has officially passed the review of the Australian Therapeutic Goods Administration (TGA) and Australian Register of Therapeutic Goods (ARTG). It has been approved to go on the market in Australia.

This has been another significant breakthrough for SkyWalker™ after it obtained registration certification from the National Medical Products Administration (NMPA) of China, the US Food and Drug Administration (FDA), the European Union's CE certification, and the Brazilian National Health Surveillance Agency (ANVISA). MicroPort® MedBot™ has planned to use this opportunity to benefit more patients globally through technological innovation.

According to Mr. Yu Liu, Executive Vice President and Chief Business Officer of MicroPort® MedBot™, "The approval will help MicroPort® MedBot™ accelerate its global footprint, benefit more global patients, and realize its initial ambition to 'Make Surgery Easier, Safer and Less Invasive'".

Investor Newsletter

MicroPort®

For more information, please contact:

Martin Sun
Chief Financial Officer
MicroPort Scientific Corporation
Tel: (86)(21) 38954600
Email: ir@microport.com

Leanne Li
First Vice President of Board Secretary and Legal Affairs
MicroPort Scientific Corporation
Tel: (86)(21) 38954600
Email: ir@microport.com